ABL206 / ABL Bio - LARVOL DELTA

ABL Announces Dual Antibody ADC with 'Year-End IND' at WorldADC [Google translation] (Biospectator) - "At this event, ABL Bio will present the differentiation of dual antibody ADC, non-clinical development strategy, etc. under the theme of 'Discovery and non-clinical development of dual antibody ADC candidate ABL206'....ABL Bio plans to submit an investigational new drug (IND) application for the US Phase 1 clinical trial of its dual antibody ADC ABL206 (target undisclosed) and ABL209 (target undisclosed) later this year."

Preclinical • Oncology

ABL206 & ABL209: Bispecific ADC as Next Generation of ADC May Overcome Current Clinical Limitations (ADC London 2025) - "• Investigating synergistic cancer-killing effect by targeting two different targets on cancer cells • Outlining recent discovery research of bispecific ADC • Contrasting advantages and challenges of bispecific ADC development against traditional ADC design"

Clinical • Oncology

ABL Bio accelerates R&D of 'dual antibody ADC'… Aiming to dominate the market [Google translation] (Medipana) - "To this end, the company plans to apply for INDs for two key pipelines in the second half of this year and one in the first half of next year, centered around its US corporation...'Among the three key candidates, 'ABL206' and 'ABL209' are scheduled to submit an IND (investigational new drug application) in the second half of this year, and 'ABL210' next year,' adding, 'We expect to quickly establish a position in the global dual antibody market.'"

IND • Oncology

ABL, which pulled in 140 billion, has a reason to believe? 'New drug royalty' [Google translation] (HIT News) - "The dual antibody ADC pipeline being developed through this paid-in capital increase includes ABL206; ABL209; ABL210, etc. The company plans to establish an early market in this field, submit a phase 1 clinical trial plan (IND) by the end of next year, and conduct phase 1 clinical trials starting in 2026."

IND • New P1 trial • Oncology • Solid Tumor

Lee Sang-hoon, CEO of ABL, “Securing 400 billion + α funds… Focusing on ’dual antibody ADC’“ [Google translation] (Money Today) - "ABL Bio...an 'ADC (antibody-drug conjugate) powerhouse', has presented a new vision for the future. It is a leap forward to 'ABL 2.0' that will increase the scale of technology transfer by raising the clinical stage to mid- and late-stage. The goal is to secure KRW 400 billion in funds by 2025 and continuously maintain the scale of 'KRW 400 billion + α' thereafter to increase the speed of pipeline development...On the 3rd, ABL Bio held online and offline corporate briefings and unveiled its future vision, 'ABL 2.0'...ABL Bio's dual antibody ADC pipeline consists of three: 'ABL206', 'ABL209', and 'ABL210'....The company plans to complete the IND (clinical trial plan) submission for the pipeline by the end of next year and begin intensive development through its U.S. corporation in 2026."

Financing • IND • Bladder Cancer • Colon Cancer • Esophageal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer